ModifiedCentenePolicy HIM.PA.173

Palbociclib (Ibrance) coverage

Defines Centene medical necessity and prior authorization criteria for palbociclib (Ibrance) use in adults, primarily for HR-positive, HER2-negative advanced or metastatic breast cancer and select off-label use (well-differentiated/dedifferentiated liposarcoma). Applies to HIM line of business members and providers requesting coverage.

Policy Summary

PayerCentene

PolicyPalbociclib (Ibrance) coverage

Policy CodePolicy HIM.PA.173

Change TypeStep therapy requirement addednew FDA indication and sarcoma formulation/approval updates

Effective DateJan 1, 2024

Next Review Date

Key ActionSubmit prior authorization with documentation of diagnosis, prior use of Kisqali and Verzenio or a valid step-therapy bypass, and relevant biomarker testing.

SourceLink

POLICY UPDATE CHANGES

For initial therapy, wording changed from 'failure of Kisqali and Verzenio' to 'must use Kisqali and Verzenio'.

Added criteria for step therapy bypass for states with regulations against redirections in cancer and added Appendix E 'states with regulations against redirections in cancer'.

Added newly approved indication for endocrine-resistant, PIK3CA‑mutated, HR‑positive, HER2‑negative, locally advanced or metastatic breast cancer to criteria.

For soft tissue sarcoma, removed 'retroperitoneal' and added requirement that request is for capsule formulation per NCCN.

Extended initial approval duration from 6 months to 12 months for soft tissue sarcoma.

Appendix E updated to add state IN (Indiana).

12 monthsSoft tissue sarcoma initial approval

125 mg/day

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

COVERAGE CRITERIA — Breast Cancer (initial therapy)

Covered when ALL of the following are met for Breast Cancer initial therapy

Breast Cancer Initial Approval

Diagnosis and prescriber: 1) Diagnosis of breast cancer; 2) Prescribed by or in consultation with an oncologist; 3) Age ≥ 18 years;
Disease characteristics: 4) Disease is HR-positive (ER and/or PR positive) and HER2-negative, and advanced (including locally advanced), recurrent, or metastatic;
Step therapy requirement or bypass: 5) Member meets one of the following unless disease is PIK3CA-mutated: a) Must use Kisqali (ribociclib) and Verzenio (abemaciclib) prior to palbociclib unless both are contraindicated or clinically significant adverse effects are experienced; OR b) Request is for treatment in a state with regulations against step therapy/redirections in certain oncology settings (see Appendix E).
Policy language changed from 'failure of Kisqali and Verzenio' to 'must use Kisqali and Verzenio'
Combination regimen: 6) Palbociclib (Ibrance) is prescribed in combination with one of the following: a) an aromatase inhibitor as initial endocrine-based therapy (if male, plus testicular suppression); OR b) fulvestrant; OR c) inavolisib and fulvestrant when disease is PIK3CA-mutated and there is recurrence or progression on or after adjuvant endocrine therapy (if male, plus testicular suppression);
Premenopausal females: 7) If premenopausal or perimenopausal female, member has undergone ovarian ablation or is receiving ovarian suppression;
Prior CDK4/6 exposure: 8) Member has not previously experienced disease progression while on a CDK4/6 inhibitor; 9) Palbociclib is not prescribed concurrently with another CDK4/6 inhibitor;
Formulation and dosing: 10) For brand Ibrance requests, member must use generic palbociclib if available unless contraindicated; 11) Requested dose meets one of the following: a) Does not exceed 125 mg per day AND 1 capsule/tablet per day on Days 1–21 of a 28-day cycle; OR b) Dose is supported by practice guidelines or peer-reviewed literature for the indicated or relevant off-label use (prescriber must submit supporting evidence).

COVERAGE CRITERIA — Soft Tissue Sarcoma (off-label)

Off-label coverage for Soft Tissue Sarcoma (must meet all)

Liposarcoma Initial Approval

Diagnosis and prescriber: 1) Diagnosis of well-differentiated or dedifferentiated liposarcoma; 2) Prescribed by or in consultation with an oncologist; 3) Age ≥ 18 years;
Disease and formulation: 4) Disease is unresectable; 5) Request is for capsule formulation; 6) Prescribed as a single agent;
Concurrent therapy and dosing: 7) Not prescribed concurrently with another CDK4/6 inhibitor; 8) For brand requests, member must use generic palbociclib if available unless contraindicated; 9) Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines/peer-reviewed literature (prescriber must submit supporting evidence).

COVERAGE CRITERIA — Continuation (renewal)

Continuation (renewal) approval — All indications in Section I (must meet all)

Continuation Criteria

Current therapy: 1) Member is currently receiving palbociclib via the Centene benefit, or documentation supports current receipt for at least 30 days;
Clinical response: 2) Member is demonstrating clinical benefit or responding positively to therapy;
Concurrent therapy and dosing: 3) Palbociclib is not prescribed concurrently with another CDK4/6 inhibitor; 4) If indication is breast cancer, current dose is ≥ 75 mg per day; 5) For brand requests, member must use generic palbociclib if available unless contraindicated; 6) If request is for a dose increase, new dose must either not exceed 125 mg per day and 1 capsule/tablet per day on Days 1–21 of a 28-day cycle, OR be supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Revised coverage criteria highlights

Policy-level coverage criteria updates and indication-specific rules described in the revision history.

Breast cancer initial therapy step: For initial therapy in HR-positive/HER2-negative breast cancer, the policy requires use of Kisqali (ribociclib) and Verzenio (abemaciclib) prior to palbociclib where applicable.

Wording changed from 'failure of Kisqali and Verzenio' to 'must use Kisqali and Verzenio'.

Step therapy bypass: A step therapy bypass is permitted where state regulations prohibit redirections in cancer; Appendix E lists affected states (IN added).

Applies per state law and Appendix E

Soft tissue sarcoma updates: For soft tissue sarcoma, the policy removed the 'retroperitoneal' anatomic-site limitation and requires that requests be for the capsule formulation; initial approval duration was extended to 12 months.12 months approval

Aligned with NCCN per document

Non‑FDA indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with Centene's off‑label use policy HIM.PA.154 or other applicable evidence of coverage documents. Additionally, use of palbociclib as adjuvant therapy for early‑stage breast cancer (stage 0–III) is explicitly excluded from coverage.

Requests for palbociclib to treat soft tissue sarcoma must be for the capsule formulation to meet the policy's NCCN‑aligned criteria. The policy removed the previous anatomic‑site limitation (e.g., 'retroperitoneal') and now requires documentation that the requested product is the capsule formulation; requests for non‑capsule formulations may not meet criteria.

For disease progression that occurs while a member is receiving a CDK4/6 inhibitor, the available evidence does not support retreatment with a different CDK4/6 inhibitor‑containing regimen. Such retreatment is considered unsupported by data and is not consistent with the policy's medical necessity determination unless compelling, peer‑reviewed evidence is provided.

What Providers Must Do

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must demonstrate that all approval criteria are met, including diagnosis, age, oncologist involvement, biomarker/Receptor (HR/HER2/PIK3CA) status, prescribed combination therapy, dosing limits, and that the member has not had prior progression on a CDK4/6 inhibitor. Prior authorization requests should include clinical justification when step therapy requirements are bypassed (see items).

Affected product: palbociclib (Ibrance)
Prior authorization/approval duration: initial approval per policy criteria (see clinical policy)

Step Therapy

Step Therapy Requirement for Breast Cancer

Step therapy requires that, for initial treatment of HR-positive, HER2-negative, advanced/recurrent/metastatic breast cancer, the member must have used the alternative CDK4/6 inhibitors Kisqali (ribociclib) and Verzenio (abemaciclib) prior to approval of palbociclib unless both are contraindicated or clinically significant adverse effects were experienced. For states or situations where redirection/step therapy is prohibited (see Appendix D and Appendix E), or for Illinois HIM requests per IL HB 5395 effective 01/01/2026, the step therapy requirement is bypassed.

Dosing Regimens and Supported Combinations

Regimen	Indication	Dose / Schedule	Coverage
Palbociclib in combination with an aromatase inhibitor
Breast cancer: with an aromatase inhibitor as initial endocrine-based therapy
125 mg PO once daily on Days 1–21 of a 28‑day cycle (maximum 125 mg/day)
Covered when all policy criteria are met (including prescriber, age ≥18, HR‑positive/HER2‑negative disease, step therapy requirements unless bypass applies, and dosing within limits)

Regimen	Indication	Dose / Schedule	Coverage
Palbociclib in combination with fulvestrant
Breast cancer: in combination with fulvestrant after progression on endocrine therapy
125 mg PO once daily on Days 1–21 of a 28‑day cycle (maximum 125 mg/day)
Covered when all policy criteria are met (including prescriber, age ≥18, HR‑positive/HER2‑negative disease, prior endocrine therapy, and dosing within limits)

Regimen	Indication / Biomarker requirement	Dose / Schedule	Coverage
Palbociclib in combination with inavolisib and fulvestrant
Endocrine‑resistant, PIK3CA‑mutated, HR‑positive, HER2‑negative locally advanced or metastatic breast cancer — disease must be PIK3CA‑mutation positive as detected by an FDA‑approved test
125 mg PO once daily on Days 1–21 of a 28‑day cycle (maximum 125 mg/day) or regimen per FDA‑approved labeling/guidelines
Covered when all policy criteria are met (including documented PIK3CA mutation, prior adjuvant endocrine therapy criteria where applicable, prescriber, and other standard requirements)

Regimen	Indication	Dose / Schedule	Coverage
Palbociclib capsules as a single agent
Off‑label: Unresectable well‑differentiated or dedifferentiated liposarcoma
Dose at or below FDA maximum for approved indications (125 mg PO once daily Days 1–21 of a 28‑day cycle) or alternative dose supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence)
Covered when all off‑label criteria are met (including diagnosis, oncologist prescriber, age ≥18, unresectable disease, capsule formulation, single‑agent use, and documentation supporting dose if outside FDA limits)

Regimen / Formulation	Indication	Approval Duration	Coverage
Palbociclib — capsule formulation (request must be for capsule formulation)
Soft tissue sarcoma (per NCCN: e.g., well‑differentiated/dedifferentiated liposarcoma and other NCCN‑recommended sarcoma contexts)
Initial approval duration: 12 months
Covered when policy criteria are met and request is specifically for capsule formulation per updated NCCN‑aligned requirement (site limitation removed); prior authorization required

Dose Limits and Coding References

Dose limits

Maximum daily dose125 mg/day maximum

Standard dosing schedule125 mg PO once daily on Days 1–21 of a 28‑day cycle

Maximum per-cycle administrationOne capsule/tablet per day on dosing days (no more than 1 unit/day)

Line of Therapy Rules

first-line | second-line

Line of therapy for breast cancer: Ibrance is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy OR with fulvestrant after progression on endocrine therapy; NCCN supports fulvestrant combinations in first or second line (category 1).

first-line

Initial therapy (breast cancer) step requirement: For initial therapy, the policy requires prior use of Kisqali and Verzenio before palbociclib unless a state-specific bypass applies (see Appendix E).

Biomarker Testing Requirements

PIK3CA mutation

Required biomarker testPIK3CA mutation must be detected by an FDA‑approved test

Indication tied to resultDetection required for use of palbociclib in combination with inavolisib and fulvestrant for endocrine‑resistant disease

Source of requirementRequirement aligns with FDA approved indication in prescribing information

PIK3CA

PIK3CA mention in policy updatesPIK3CA referenced as part of newly approved endocrine‑resistant breast cancer indication

Role in regimen selectionPIK3CA status required when prescribing palbociclib plus inavolisib and fulvestrant

Key Definitions and Background

Palbociclib (Ibrance) is a cyclin‑dependent kinase 4/6 (CDK4/6) inhibitor indicated in combination with endocrine therapy for hormone receptor–positive (HR‑positive), HER2‑negative advanced or metastatic breast cancer. Indications include use with an aromatase inhibitor as initial endocrine‑based therapy or with fulvestrant after progression on endocrine therapy; the FDA‑labeled indication for palbociclib has also been expanded to include combination use with inavolisib and fulvestrant for selected PIK3CA‑mutated, endocrine‑resistant disease. Clinical and dosing recommendations in this policy align with FDA prescribing information and relevant NCCN guidance.

HR‑positive

DefinitionHormone receptor–positive: estrogen receptor (ER) and/or progesterone receptor (PR) positive

AbbreviationTerm abbreviated in policy as 'HR‑positive'

RelevanceRequired disease characteristic for covered breast cancer indications

HER2‑negative

Policy Summary

PayerCentene

PolicyPalbociclib (Ibrance) coverage

Policy CodePolicy HIM.PA.173

Change TypeStep therapy requirement addednew FDA indication and sarcoma formulation/approval updates

Effective DateJan 1, 2024

Next Review Date

Key ActionSubmit prior authorization with documentation of diagnosis, prior use of Kisqali and Verzenio or a valid step-therapy bypass, and relevant biomarker testing.

SourceLink

On This Page

Documentation Required

Required Clinical Documentation

Providers must submit supporting documentation with the prior authorization request. Include office chart notes, diagnostic reports, pathology/immunohistochemistry results documenting HR and HER2 status, PIK3CA mutation status when applicable, prior systemic therapy history, and any documentation of intolerance or contraindication to Kisqali and Verzenio if requesting a step therapy bypass.

Office chart notes and relevant clinic visit documentation
Lab/pathology reports showing ER/PR, HER2, and PIK3CA status (if applicable)
Documentation of prior use of Kisqali and Verzenio, including dates and reason for discontinuation, or documentation supporting contraindication/intolerance
Treatment plan specifying combination endocrine agent (e.g., aromatase inhibitor, fulvestrant) and any required ovarian suppression in pre-/perimenopausal females

Denial Risk

Insufficient Documentation / Denial Risk

Requests lacking sufficient documentation that the member meets step therapy or other approval criteria (diagnosis, biomarker status, prior therapies, oncologist involvement, age, dosing) may be denied. Providers should document prior use of required therapies or provide clear clinical rationale and supporting records for any step therapy bypass request.

Insufficient documentation of prior Kisqali and Verzenio use or lack of documented contraindication/intolerance may result in denial.
Requests for non‑FDA approved indications without supporting evidence per off-label policy (HIM.PA.154) may be denied.
Use as adjuvant therapy in early-stage (stage 0-III) breast cancer is not authorized under this policy.